IL6 (P05231) - Overview - Molecular Target Synopsis
Also Known as IL6_HUMAN, IL6, IFNB2
Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Required for the generation of T(H)17 cells. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation.
|Protein Length||Ensembl Gene||Ensembl Transcript||Ensembl Protein||Uniprot Isoform|
|212||ENSG00000136244||ENST00000258743, ENST00000404625||ENSP00000258743, ENSP00000385675||P05231-1|
|IL6 is targeted by Approved Drug Siltuximab. (see details)|
UniProt: IL6 is active in the following subcellular-locations: Secreted.
GO terms: IL6 is active in the following subcellular-locations: cytoplasm, external side of plasma membrane, extracellular region, extracellular space, interleukin-6 receptor complex.
|Please click the link to see mutations reported in COSMIC - Cell Lines Project|
|Please click the link to see mutations reported in COSMIC|
|Please click the link to see mutations reported in Cancer Gene Census|
|Please click the link to see mutations reported in ICGC|